BioCentury | Jan 25, 2020
Product Development

Radiotherapy blasts forward

...molecules, antibodies or other targeting domains, such as the phospholipid ether (PLE) vector developed by Cellectar...
BioCentury | Dec 19, 2018
Distillery Therapeutics

Inflammation; pulmonary

...oral PI3K inhibitor, in Phase I through Phase III testing for a variety of cancers. Cellectar...
BioCentury | Jul 17, 2018
Clinical News

Cellectar's CLR 131 reduces tumor burden by 94% in patient with Waldenström's macroglobulinemia

...post infusion. The patient was administered a second dose of CLR 131 on day 123. Cellectar...
...B cell hematologic malignancies. CLR 131 is an iodine-radiolabeled small molecule phosphoinositide 3-kinase (PI3K) inhibitor. Cellectar...
...overall survival (OS) Status: Phase II data Milestone: NA Jaime De Leon CLR 131, I-131-CLR1404 (HOT), (131)I-CLR1404 HOT Cellectar...
BioCentury | Oct 20, 2017
Financial News

Cellectar raises $7.8M in registered direct offering

...On Oct. 12, Cellectar Biosciences Inc. (NASDAQ:CLRB) raised $7.8 million through the sale of shares and...
...$7.8 million through the sale of shares and convertible stock in a registered direct offering. Cellectar...
...an iodine-radiolabeled small molecule phosphoinositide 3-kinase (PI3K) inhibitor. Cellectar Biosciences Inc. (NASDAQ:CLRB), Madison, Wis. Allison Johnson CLR 131 Cellectar...
BioCentury | Oct 13, 2017
Company News

Cellectar and Pierre Fabre extend PDC deal

...Fabre's cytotoxic payloads with Cellectar's phospholipid ether drug conjugates (see BioCentury, Jan. 4, 2016 ). Cellectar...
...inquiries. Cellectar Biosciences Inc. (NASDAQ:CLRB), Madison, Wisc. Pierre Fabre Group , Castres, France Business: Cancer Shannon Lehnbeuter Cellectar...
BioCentury | Aug 18, 2017
Clinical News

Cellectar reports OS of 22.5 months in Phase I MM trial of CLR 131

...IV CLR 131 led to median OS of 13.2 and 6.7 months, respectively. This quarter, Cellectar...
...inhibitor, is also in a Phase II trial to treat MM and other hematologic malignancies. Cellectar...
...Status: Additional Phase I data Milestone: Additional Phase I data (3Q17) Jaime De Leon (131)I-CLR1404 HOT CLR 131 I-131-CLR1404 (HOT) Cellectar...
BioCentury | Apr 4, 2017
Clinical News

CLR 131: Ph II started

...myeloma (MM). Patients will have the option to receive a second dose 75-180 days later. Cellectar...
...median overall survival (OS) Status: Phase II started Milestone: Phase II data (2H17) Julian Zhu CLR 131 I-131-CLR1404 (HOT) Cellectar...
BioCentury | Mar 17, 2017
Company News

WARF, Cellectar deal

...The foundation granted Cellectar rights to IP covering the method of use for Cellectar's CLR 131...
...Alumni Research Foundation , Madison, Wis. Cellectar Biosciences Inc. (NASDAQ:CLRB), Madison, Wis. Business: Cancer Chris Lieu CLR 131 Cellectar...
BioCentury | Jan 6, 2017
Finance

Good riddance

...NYSE-M:PTN) (A) 12/1/16 $16.5 NA $68.0 NA Xencor Inc. (NASDAQ:XNCR) 12/1/16 $126.5 $1,113.9 $1,221.6 10% Cellectar...
BioCentury | Dec 1, 2016
Financial News

Cellectar completes follow-on

...share sold. The five-year warrants are exercisable at $1.50. Cellectar Biosciences Inc. (NASDAQ:CLRB), Madison, Wis. Alicia Parker Cellectar...
Items per page:
1 - 10 of 40
BioCentury | Jan 25, 2020
Product Development

Radiotherapy blasts forward

...molecules, antibodies or other targeting domains, such as the phospholipid ether (PLE) vector developed by Cellectar...
BioCentury | Dec 19, 2018
Distillery Therapeutics

Inflammation; pulmonary

...oral PI3K inhibitor, in Phase I through Phase III testing for a variety of cancers. Cellectar...
BioCentury | Jul 17, 2018
Clinical News

Cellectar's CLR 131 reduces tumor burden by 94% in patient with Waldenström's macroglobulinemia

...post infusion. The patient was administered a second dose of CLR 131 on day 123. Cellectar...
...B cell hematologic malignancies. CLR 131 is an iodine-radiolabeled small molecule phosphoinositide 3-kinase (PI3K) inhibitor. Cellectar...
...overall survival (OS) Status: Phase II data Milestone: NA Jaime De Leon CLR 131, I-131-CLR1404 (HOT), (131)I-CLR1404 HOT Cellectar...
BioCentury | Oct 20, 2017
Financial News

Cellectar raises $7.8M in registered direct offering

...On Oct. 12, Cellectar Biosciences Inc. (NASDAQ:CLRB) raised $7.8 million through the sale of shares and...
...$7.8 million through the sale of shares and convertible stock in a registered direct offering. Cellectar...
...an iodine-radiolabeled small molecule phosphoinositide 3-kinase (PI3K) inhibitor. Cellectar Biosciences Inc. (NASDAQ:CLRB), Madison, Wis. Allison Johnson CLR 131 Cellectar...
BioCentury | Oct 13, 2017
Company News

Cellectar and Pierre Fabre extend PDC deal

...Fabre's cytotoxic payloads with Cellectar's phospholipid ether drug conjugates (see BioCentury, Jan. 4, 2016 ). Cellectar...
...inquiries. Cellectar Biosciences Inc. (NASDAQ:CLRB), Madison, Wisc. Pierre Fabre Group , Castres, France Business: Cancer Shannon Lehnbeuter Cellectar...
BioCentury | Aug 18, 2017
Clinical News

Cellectar reports OS of 22.5 months in Phase I MM trial of CLR 131

...IV CLR 131 led to median OS of 13.2 and 6.7 months, respectively. This quarter, Cellectar...
...inhibitor, is also in a Phase II trial to treat MM and other hematologic malignancies. Cellectar...
...Status: Additional Phase I data Milestone: Additional Phase I data (3Q17) Jaime De Leon (131)I-CLR1404 HOT CLR 131 I-131-CLR1404 (HOT) Cellectar...
BioCentury | Apr 4, 2017
Clinical News

CLR 131: Ph II started

...myeloma (MM). Patients will have the option to receive a second dose 75-180 days later. Cellectar...
...median overall survival (OS) Status: Phase II started Milestone: Phase II data (2H17) Julian Zhu CLR 131 I-131-CLR1404 (HOT) Cellectar...
BioCentury | Mar 17, 2017
Company News

WARF, Cellectar deal

...The foundation granted Cellectar rights to IP covering the method of use for Cellectar's CLR 131...
...Alumni Research Foundation , Madison, Wis. Cellectar Biosciences Inc. (NASDAQ:CLRB), Madison, Wis. Business: Cancer Chris Lieu CLR 131 Cellectar...
BioCentury | Jan 6, 2017
Finance

Good riddance

...NYSE-M:PTN) (A) 12/1/16 $16.5 NA $68.0 NA Xencor Inc. (NASDAQ:XNCR) 12/1/16 $126.5 $1,113.9 $1,221.6 10% Cellectar...
BioCentury | Dec 1, 2016
Financial News

Cellectar completes follow-on

...share sold. The five-year warrants are exercisable at $1.50. Cellectar Biosciences Inc. (NASDAQ:CLRB), Madison, Wis. Alicia Parker Cellectar...
Items per page:
1 - 10 of 40